Recent blog posts
Skyhawk Therapeutics Announces Successful Phase 1 Results for SKY-0515 in Huntington's Disease
Latest Hotspot
3 min read
Skyhawk Therapeutics Announces Successful Phase 1 Results for SKY-0515 in Huntington's Disease
16 July 2024
Skyhawk Therapeutics Reports Positive Topline Results from Phase 1 Trial of SKY-0515 for Huntington’s Disease, Achieving 72% Reduction in Huntingtin mRNA.
Read →
MEKanistic Therapeutics Inc.'s MTX-531 Shows Tolerability and Tumor Reduction in Preclinical Studies
Latest Hotspot
3 min read
MEKanistic Therapeutics Inc.'s MTX-531 Shows Tolerability and Tumor Reduction in Preclinical Studies
16 July 2024
MEKanistic Therapeutics Inc.’s innovative dual-target therapy, MTX-531, shows considerable tolerability and sustained tumor reduction in preclinical cancer studies.
Read →
FDA Approves Rgenta Therapeutics' IND for RGT-61159, an Oral RNA Modulator Targeting ACC and CRC
Latest Hotspot
3 min read
FDA Approves Rgenta Therapeutics' IND for RGT-61159, an Oral RNA Modulator Targeting ACC and CRC
15 July 2024
Rgenta Therapeutics secures FDA nod for IND application of RGT-61159, an oral RNA modulator intended to stop MYB production, targeting Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC).
Read →
Avalo Therapeutics Announces IND Activation for AVTX-009, Targeting Hidradenitis Suppurativa Treatment
Latest Hotspot
3 min read
Avalo Therapeutics Announces IND Activation for AVTX-009, Targeting Hidradenitis Suppurativa Treatment
15 July 2024
Avalo Therapeutics Reports IND Activation for AVTX-009, an anti-IL-1β Antibody, Aimed at Treating Hidradenitis Suppurativa.
Read →
uniQure Reports Positive Early Results in AMT-130 Phase I/II Trials for Huntington's Disease
Latest Hotspot
3 min read
uniQure Reports Positive Early Results in AMT-130 Phase I/II Trials for Huntington's Disease
15 July 2024
uniQure Releases Promising Interim Results Showing Reduced Disease Progression in Phase I/II AMT-130 Trials for Huntington’s Disease.
Read →
Prelude Therapeutics and Merck to Test PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers
Latest Hotspot
3 min read
Prelude Therapeutics and Merck to Test PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers
15 July 2024
The agreement specifies that the Phase 2 clinical trial will evaluate the effectiveness of PRT37890, a new and highly selective SMARCA2 degrader, and Merck's KEYTRUDA in treating cancers with SMARCA4 mutations.
Read →
Kiniksa Pharmaceuticals Starts Phase 2b Trial for Abiprubart in Sjögren’s Disease
Latest Hotspot
3 min read
Kiniksa Pharmaceuticals Starts Phase 2b Trial for Abiprubart in Sjögren’s Disease
15 July 2024
Kiniksa Pharmaceuticals International announced that it has begun enrolling participants for the Phase 2b clinical trial of abiprubart in Sjögren’s Disease.
Read →
AEON Biopharma Reveals Strategic Shift to Focus on ABP-450 Biosimilar Development
Latest Hotspot
3 min read
AEON Biopharma Reveals Strategic Shift to Focus on ABP-450 Biosimilar Development
15 July 2024
AEON Biopharma revealed their intention to proceed with a crucial clinical development trial in cervical dystonia for their main product, ABP-450 (prabotulinumtoxinA) injection.
Read →
Lilly to Buy Out Morphic to Enhance Treatment Options for Inflammatory Bowel Disease Patients
Latest Hotspot
3 min read
Lilly to Buy Out Morphic to Enhance Treatment Options for Inflammatory Bowel Disease Patients
10 July 2024
Eli Lilly and Company along with Morphic Holding, Inc. have revealed a formal agreement in which Lilly will purchase Morphic.
Read →
Ligand is set to purchase APEIRON Biologics AG in a deal valued at $100 million
Latest Hotspot
3 min read
Ligand is set to purchase APEIRON Biologics AG in a deal valued at $100 million
10 July 2024
Ligand Pharmaceuticals Incorporated revealed that it has finalized a definitive contract to purchase APEIRON Biologics AG.
Read →
iTeos Announces First Patient Dosed in Phase 3 GALAXIES Lung-301 Trial, Receives $35 Million from GSK
Latest Hotspot
3 min read
iTeos Announces First Patient Dosed in Phase 3 GALAXIES Lung-301 Trial, Receives $35 Million from GSK
10 July 2024
iTeos Reports Initial Patient Dosed in GALAXIES Lung-301 Phase 3 Trial, Securing $35 Million Milestone Payment from GSK.
Read →
SciRhom Raises EUR 63 Million in Series A to Boost iRhom2 Therapy for Autoimmune Diseases
Latest Hotspot
3 min read
SciRhom Raises EUR 63 Million in Series A to Boost iRhom2 Therapy for Autoimmune Diseases
10 July 2024
SciRhom GmbH has declared the successful conclusion of a EUR 63 million Series A funding round.
Read →